Peer review

· NHMRC Grant Reviewer (~3/year past 14 years)

· NHMRC Grant Review Panel member for project grants (2007, 2011)

· NHMRC Grant Review Panel for Early Career Fellowships (2009, 2013)

· Other grant assessments include Arthritis Australia, Anti-Cancer Council of Victoria, Diabetes Australia, Israel Science Foundation, JDRF International, National Arthritis Spain.

· Reviewer for numerous journals incl. J Biol Chem, Exp Cell Res, Ann Rheum Dis, J Immunol, Arthr Rheum, Immunol, Br J Derm, J Invest Derm, J Rheum (usually >=2 each/ year)

· Editorial board; Frontiers in Bioscience, Pathobiology, Wound Practice and Research

· Managing Editor for Special Issue “Multifunctional activated protein C” in Frontiers of Bioscience 2013

· In the past 6 years he has published, as senior author, in the top-ranked journals in disciplines of:

o Dermatology -J Invest Derm 2008 (received an editorial comment)

o Arthritis-Arthr Rheum 2007, 2009, 2012 Ann Rheum Dis 2007

and other journals of note- J Biol Chem 2007, 2011; 2012, J Cell Mol Med 2009, Faseb J 2010, Cell Mol Life Sciences 2010, Am J Path 2011

· Holds 3 accepted patents (see RGMS for details) and 2 patent applications - Treatments for i) inflammatory skin disorders and ii) bone defects

Societies

· Current Vice-President, Australasian Wound and Tissue Repair Society (AWTRS, 2012-2014)

· Past President, Australian and New Zealand Microcirculation Society (ANZMS, 2005-7)

· Executive Member, Institute of Bone and Joint Research Board (since 1997)

· Key area co-ordinator (Research Advisory Committee) representing Regenerative Medicine at Royal North Shore Hospital (since 2005)

· Past Chair, Executive committee, Gore Hill Research Laboratories Animal Research and Electron Microscopy Unit, Royal North Shore Hospital

· Current society memberships: Australian Rheumatology Association, International Society on Thrombosis and Haemostasis, AWTRS, ANZMS.

Supervision

· As a senior researcher, he is committed to supervising/mentoring students and post-docs. During the past 5 years, Dr Jackson has co-supervised (including current) 10 PhD, 7 Honours students, 4 Postdoctoral fellows, 7 International Visiting Post-docs/Scholars.

· In the past 3 years, 2 PhD student for whom Dr Jackson was primary supervisor, plus 2 PhD students that Dr Jackson co-supervised and 4 Honours students have graduated.

· Currently (co-)supervising 4 PhD students, 2 Honours student and mentoring 3 post-doctoral fellows and 1 Visiting fellow.

· In 2012, Dr Jackson’s post-docs won Best ECR oral presentation at the AWTRS Scientific Meeting (Dr Kelly McKelvey) at Darling Harbour, and Best Overall Oral presentation at NSW ARA Annual Scientific Conference, Central Coast, NSW (Dr Meilang Xue).

Grants

In the past 4 years, Dr Jackson has received:

· Four NHMRC grants (three as CIA)

· JDRF International Innovative grant- C. Jackson, M Xue and L Harrison, 2008-09, US$102,000;

· Korea National Research Foundation “Role of Activated protein C in treatment of bisphosphonate-induced diseases including osteonecrosis of the jaw”, Sang-Youel Park and Chris Jackson, 2010-E00019, A$100,000, 2010-2013

· Ray and Pam Robinson award from Arthritis Australia in 2009 and 2013, $40,000 each

· Five University of Sydney Bridging Support grants for being CI on near miss NHMRC project grants scoring high 5 (three in 2009 and one each in 2010, 2011 and 2013 - 2 as CIA), each for $40K-$50K

Conferences

· Member, Conference organiser committees for 11 scientific conferences, currently Australian Wound and Tissue Research Society Scientific meeting, Gold Coast, 2014

· Speaker, International Vascular Biology Meeting, Weisbaden, Germany, July, 2012

· Invited speaker, Chair and Session organiser, Australian and New Zealand Microcirculation Society, Margaret River, Western Australia, Nov 2011

· Plenary speaker, South Australian Rheumatology Association Annual Scientific Meeting, Adelaide, Nov, 2010

· Invited speaker and Chair, International Microcirculation Congress, Paris, Sept 2010

· Speaker, European Tissue Repair Society, Gent, Belgium, Aug 2010

· Invited speaker, Australian Wound and Tissue Repair Society (AWTRS) Scientific Meeting, Perth, March 2010

· Invited speaker and Chair, ANZ Microcirculation Society, Queenstown, 2009

· Speaker and Chair, International Society Thrombosis and Hemostasis, Boston, 2009

· Invited speaker Australian Matrix Biology Meeting, Ettalong, Oct 2008

· Invited speaker, Inaugral AWTRS, Darwin, May 2008

Community

· Speaker, on “Rheumatoid Arthritis” at the Institute of Bone and Joint Public Forums (~200 members of public in attendance), Kolling Auditorium, Oct 2009, and Nov 2011

· Speaker, on the need for arthritis research to a large group (~4000 in attendance) of Ulysses Club members at their Annual General Meetings in Albany 2010 and Newcastle 2011

Industry

· Founder and Chief Scientific Officer - start-up company, Bioatrix, incorporated in 2012

· Attendance at the JP Morgan conference, San Francisco, Jan 2013, to present our wound healing research and upcoming clinical trials with Venture Capitalists

Translation

The research of Dr Jackson and his team has evolved to become true bench to bedside translational research. After making the original discovery, Dr Jackson has undertaken extensive basic laboratory studies, followed by animal studies to obtain proof-of-concept that APC heals chronic wounds. He then linked with his clinical colleagues to conduct open label human trials and the positive results allowed him to progress to Phase II clinical trials to use APC in diabetic chronic wounds. Dr Jackson is now poised to reveal a new contribution of APC to the field of bone healing.